Application of outer membrane vesicle of Neisseria meningitidis serogroup B as a new adjuvant to induce strongly Th1-oriented responses against HIV-1.
Despite the worldwide efforts made in the field of HIV vaccine development, an efficient AIDS vaccine strategy is still vague. Virus-like particles (VLPs) are one of the introduced aspects for HIV vaccine development since the non-replicative nature of HIV VLPs, resulting from the lack of viral genomic RNA, makes them suitable for broad applications. We have previously designed and introduced non-infectious VLPs (mzNL4-3) by introduction of a deletion mutation in the reverse transcriptase and integrase coding regions of HV-1. There are evidences suggesting that an effective cellular immune response against HIV-1 is able to control and suppress viremia during primary and chronic HIV infections. In the present study we have evaluated the potency of mzNL4-3 VLPs mixed with Neisseria meningitidis serogroup B outer-membrane vesicle (OMV), which is among the microbial components with proved adjuvant properties, to induce humoral and cellular responses against HIV-1. Analysis of anti-HIV-1 responses elicited in immunized BALB/c mice following different immunization regimens indicated OMV+VLP as an immunopotent combination which significantly induced anti-HIV-1 IgG with IgG2a dominancy. Results of cytokine and ELISpot assays also showed the capability of VLP+OMV immunogen for effective induction of IFN-gamma; and IL4 secreting cells and further suggested the promotion of Th1-oriented response that was evidenced with the increased IFN-γ/IL4 secretion ratio. According to our study, HIV-1 VLPs combined with N. meningitidis B OMVs seem to be a promising approach in vaccine development against HIV-1.
Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
Mohammad Reza
MR
Aghasadeghi
Ali Sharifat
AS
Salmani
Seyed Mehdi
SM
Sadat
Foozieh
F
Javadi
Arash
A
Memarnejadian
Rouhoullah
R
Vahabpour
Rezvan
R
Zabihollahi
Arfa
A
Moshiri
Seyed Davar
SD
Siadat
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology*; D016207:Cytokines / Q000378:metabolism; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology*; D007111:Immunity, Cellular / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology*; D018417:Th1 Cells / Q000276:immunology*; D058425:Vaccines, Virus-Like Particle / Q000276:immunology
D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D001425:Bacterial Outer Membrane Proteins; D016207:Cytokines; D058425:Vaccines, Virus-Like Particle